Clinical Trial Update: A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ABT-263 in relapsed or refractory chronic lymphocytic leukemia (Phase 1/Phase 2) completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• ABT-263 (navitoclax)

Snippet

Sponsor: AbbVie | Conditions: Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-06-13